Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Date:2/29/2008

cally indicated, oral ABILIFY in a range of 10 mg/day to 30 mg/day should replace ABILIFY Injection as soon as possible. The safety of doses of ABILIFY Oral or ABILIFY Injection above 30 mg/day has not been evaluated in clinical trials.

IMPORTANT SAFETY INFORMATION and INDICATIONS for ABILIFY

INDICATIONS:

-- ABILIFY is indicated for acute and maintenance treatment of adults

with manic or mixed episodes associated with Bipolar I Disorder with

or without psychotic features

-- ABILIFY is indicated for acute treatment of pediatric patients (10 to

17 years old) with manic or mixed episodes associated with Bipolar I

Disorder with or without psychotic features

-- ABILIFY Injection is indicated for the treatment of adults with

agitation associated with Bipolar I Disorder, manic or mixed.

IMPORTANT SAFETY INFORMATION:

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). ABILIFY is not approved for the treatment of patients with dementia-related psychosis (see Boxed WARNING).

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of adjunctive ABILIFY or another antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increased risk of suicidality in adults beyond age 24. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusu
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
7. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... that widens the obstructed blood vessels. This report ... and future prospects of the market. The report ... market snapshot that provides overall information of various ... section also provides the overall information and data ...
(Date:9/2/2015)... 2, 2015 About implantable medical devices ... to replace, augment, or repair damaged tissues or ... of applications including cosmetic, spinal, cardiovascular, ophthalmic, and ... different materials such as polymers, metals, ceramics, and ... medical devices market to grow at a CAGR ...
(Date:9/2/2015)...  The report on breast cancer therapeutics: pipeline analysis ... on the basis of the molecules which are currently ... lining of milk ducts or lobules responsible for supplying ... that can spread to other cells present in the ... is referred as lobular carcinoma, while the other that ...
Breaking Medicine Technology:Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Implantable Medical Devices Market 2015-2019 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3
... Corporation (Nasdaq: SIAL ) will be presenting at ... 1:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High ...
... 23, 2011 ViewRay™, Inc., a privately held ... clearance for its radiotherapy treatment planning and delivery ... the company,s new radiation therapy system, which combines ... in the late stages of development, the integrated ...
Cached Medicine Technology:ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software 2
(Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 ... had great success in launching their Path11 Podcast with 23 episodes released since April ... is the well known Spiritual Catalyst and Linda Howe, leader in the field of ...
(Date:9/3/2015)... ... 2015 , ... Leading post-acute electronic medical record (EMR) software ... the company’s executive leadership team as VP of Product and as VP of ... product and project management. He has been with HealthWyse since 2000 in the ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... and efficient customer and technical support services to promote LodonalTM in Nigeria. The ... trial evaluating the efficacy and safety of the product. , Managing Director, Fidson ...
(Date:9/2/2015)... , ... September 03, 2015 , ... The Aspen ... services - two retreats geared towards kick-starting and inspiring wellness in the Roaring Fork ... a part of developing a whole mind-body approach to fitness - we are much ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
Breaking Medicine News(10 mins):Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2
... women receiving the same breast cancer treatments as Hispanic ... lower survival rates, were more likely to be diagnosed// ... to a study. ,For the study, ... M. D. Anderson Cancer Center and colleagues examined 2,140 ...
... According to a recent analysis by Metropolitan Transportation Authority, ... excessive dieting are among the top// causes, after the ... US subway. ,Asim Nelson, a transit ... statistics, taken between October 2005 and October 2006, shows ...
... among states and union territories to enforce screening of all ... disorder// that could lead to disabilities. ,Chandigarh ... children would be done to check any adverse fallout later. ... ,While poor people would be provided the facility ...
... giant-Coco Cola and Nestle have come together to manufacture a ... tea, caffeine and plant micronutrients. This is expected to hit ... consumers shed excess weight. ,According the chief scientist ... calories burnt. The soft drink company claims that detailed studies ...
... proposal released by Gov. Arnold Schwarzenegger recently, workers in ... benefit - to their// health and wealth. Employees will ... exempted from tax. ,The proposal is an ... reachable to the approximate 6.5 million Californians who are ...
... make you diabetic, says a study that tracked hospitalisation rates ... ,Type-two diabetes has seen a two-fold increase - from ... While scientists scramble to find explanations for the rise, experts ... , ,However, the study by Lawrence Lessner and colleagues ...
Cached Medicine News:Health News:Living Near Toxic Waste May Bring On Diabetes 2
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: